CBDV vs CBD: What All Six Registered Clinical Trials of Cannabidivarin Actually Found
| Audience | Cannabis-medicine clinicians, epileptologists and pain specialists evaluating minor cannabinoids, patients and caregivers considering CBDV products for epilepsy or autism, and athletes or employees subject to drug testing who use broad-spectrum CBD supplements |
| Primary Topic | A structured review of all six peer-reviewed clinical trials of cannabidivarin (CBDV) indexed in PubMed, examining what each trial actually tested and found |
| Source | See the six trials on PubMed |
CBDV vs CBD: What All Six Registered Clinical Trials of Cannabidivarin Actually Found
A PubMed search for cannabidivarin restricted to the Clinical Trial publication type returns exactly six peer-reviewed studies. Only two tested whether CBDV actually relieves a clinical symptom in an adequately powered, placebo-controlled design, and both came back negative. Here is what each of the six trials really shows, and does not show.
| Search Method | PubMed, query: cannabidivarin AND Clinical Trial[Publication Type] |
| Total Trials Found | Six peer-reviewed clinical trials, published 2019 to 2025 |
| Trials Testing a Clinical Symptom Endpoint | Two, both negative on their primary endpoint: focal epilepsy add-on therapy (n=162, Brodie et al 2021) and HIV-associated neuropathic pain (n=32, Eibach et al 2020) |
| Small Open-Label Safety Pilot | One: Rett syndrome epilepsy, n=5, Phase 1, nonblinded and nonrandomized (Hurley et al 2022) |
| Neuroimaging / Mechanistic Trials | Two single-dose, placebo-controlled crossover studies in adults with and without autism spectrum disorder (n=34 and n=28, Pretzsch et al 2019 and 2021), measuring brain chemistry and connectivity, not symptoms |
| Most Recent Trial | A 2025 anti-doping study (n=36) detecting CBDV in the urine of broad-spectrum CBD supplement users, not an efficacy trial (Gillham et al 2025) |
| Trials Meeting Their Primary Efficacy Endpoint | Zero of six |
The most rigorous test of CBDV came from a Phase 2, double-blind, placebo-controlled trial in 162 adults with inadequately controlled focal seizures (Brodie et al., 2021, Cannabis and Cannabinoid Research). Participants titrated to 800 mg CBDV twice daily, followed by eight weeks of stable dosing. Seizure frequency fell 40.5% in the CBDV group and 37.7% in the placebo group, a difference the trial’s own published discussion describes as showing no treatment effect (p = 0.648). The investigators note that 36% of CBDV patients were seizure responders (at least a 50% reduction) versus 33% on placebo, a narrower gap than would be expected if CBDV were doing meaningful pharmacological work, and a considerably larger placebo response than the 9% to 17% documented in prior epilepsy-trial meta-analyses.
The second efficacy trial tested CBDV (400 mg per day) against placebo for HIV-associated neuropathic pain in 32 adults, using a randomized, double-blind, crossover design with a three-week washout between arms (Eibach et al., 2020, Clinical Pharmacology and Therapeutics). Mean pain intensity was actually 0.62 points higher on CBDV than on placebo on an 11-point scale, a difference that was not statistically significant (p = 0.16) but ran in the wrong direction. The study authors concluded that they would not currently consider CBDV a clinically meaningful treatment option for neuropathic pain.
A Phase 1 trial gave oral CBDV, titrated to 10 mg/kg/day, to five girls with Rett syndrome and drug-resistant epilepsy linked to a pathogenic MECP2 variant (Hurley et al., 2022, Epilepsia). Median monthly seizure frequency fell 79%, from 32 to 7.2 seizures per month, and the drug was generally well tolerated; hypersomnolence and drooling were the only adverse events judged definitely related to CBDV.
That result is genuinely encouraging, but the trial’s own authors are explicit about what it cannot show. This was an open-label study with no control group and no randomization, in five patients, and the published discussion states plainly that the small sample size and lack of a control make it impossible to determine statistical significance. Epilepsy is a condition with well-documented natural fluctuation and a large placebo response even in blinded trials, exactly the kind of noise an uncontrolled five-patient pilot cannot separate from a real drug effect. The authors themselves call for a larger, controlled Phase 2 trial before drawing firmer conclusions.
Two single-dose, double-blind, placebo-controlled crossover studies from the same King’s College London research group gave adults a single 600 mg dose of CBDV and measured brain activity rather than behavior. In the first (Pretzsch et al., 2019, Translational Psychiatry; n=34, 17 with autism spectrum disorder), CBDV significantly increased a marker of glutamate signaling in the basal ganglia in both autistic and neurotypical participants, with no significant effect on GABA or on a second brain region studied. In the second (Pretzsch et al., 2021, Molecular Autism; n=28, 13 with autism spectrum disorder), a single dose of CBDV shifted atypical striatal functional connectivity in autistic participants toward the pattern seen in neurotypical adults.
Both studies are careful, well-designed pharmacological challenge studies, and both are explicit that they measured brain physiology after a single dose, not behavior, symptoms, or quality of life after sustained treatment. Neither trial gave CBDV to autistic patients over weeks or months and asked whether core autism symptoms improved. They are best read as a rationale for running that harder trial, not as evidence that CBDV treats autism.
The most recent of the six trials, published in 2025 in Medicine and Science in Sports and Exercise, was not designed to test whether CBDV works for anything (Gillham et al., 2025). It gave 36 healthy adults a broad-spectrum CBD supplement (150 mg per day, containing trace cannabigerol) or a matched placebo for 10 weeks and tested urine and blood for cannabinoids the World Anti-Doping Agency prohibits. CBDV, not an ingredient the product was marketed around, was detected in 68% of pre-exercise and 84% of post-exercise urine samples from the CBD group, alongside CBG; concentrations rose further after a bout of moderate-intensity exercise.
No THC or THC metabolites were detected at any timepoint, but the CBDV and CBG findings are a real, practical caution for athletes, military service members, and anyone in a safety-sensitive or drug-tested role who assumes a broad-spectrum CBD label is functionally equivalent to a CBD-isolate product. It has nothing to do with whether CBDV treats a condition, but it is the finding from these six trials most patients using these products are likely to be personally affected by.
CBDV’s trial record follows a pattern familiar from other minor cannabinoids: real, sometimes compelling preclinical and mechanistic data in animal models and brain-imaging studies, paired with negative or unconfirmed results once a compound reaches an adequately powered, placebo-controlled human efficacy trial. GW Pharmaceuticals (now part of Jazz Pharmaceuticals) discontinued its lead CBDV epilepsy program after the focal-seizure trial missed its primary endpoint, a genuine setback for a compound that had generated real scientific interest through the 2010s.
The 2025 anti-doping finding also lands amid growing scrutiny of broad-spectrum and full-spectrum CBD product labeling, where consumers and even regulated athletes often have no reliable way to know which minor cannabinoids, and at what concentration, are actually present in a given bottle.
What I find useful about laying all six trials side by side is how clearly it separates hope from evidence. The Rett syndrome result is the kind of finding that keeps a cannabinoid research program alive, and I understand why families read about it and want access now. But five patients with no control arm is a hypothesis, not a treatment protocol, and the authors of that very paper say so themselves.
For patients asking me about CBDV specifically, my honest answer today is that the human evidence does not yet support choosing it over better-studied cannabinoids for epilepsy, pain, or autism-related symptoms, and the two trials that were actually built to test clinical benefit both came back negative. I would rather tell a patient that plainly than let a Rett syndrome pilot or a brain-imaging study carry more weight than the study authors themselves place on it. If you are using a broad-spectrum CBD product and are subject to drug testing, the 2025 finding is worth a direct conversation with your care team regardless of how you feel about the efficacy question.
How to Weigh a Six-Trial Evidence Base Without Overreading Any Single Study
Six trials is a small but real number: small enough that it is tempting to cite only the ones that support a preferred conclusion, and large enough that a fair reader can actually characterize the whole picture rather than relying on any one study.
CBDV is a useful case study in the different kinds of human evidence a cannabinoid can accumulate long before, if ever, it earns a genuine efficacy claim.
Four distinctions worth keeping straight
Efficacy trial versus safety or mechanism trial
Only two of the six trials were designed to test whether CBDV relieves a specific clinical symptom against placebo. The other four tested safety, brain physiology, or an unrelated anti-doping question, and none of them can substitute for an efficacy result.
Negative trial versus absence of evidence
The epilepsy and pain trials are not simply inconclusive; both were adequately designed, ran their planned analysis, and did not find a treatment effect. That is a negative result, not a data gap.
Uncontrolled pilot versus controlled trial
The Rett syndrome result looks the most dramatic on paper, a 79% median seizure reduction, but its own authors say the lack of a control group and blinding make it impossible to know how much of that reflects CBDV rather than natural fluctuation, expectation, or increased clinical attention.
Brain marker versus clinical symptom
The two neuroimaging trials found statistically real changes in glutamate signaling and functional connectivity after a single CBDV dose. That is a meaningful finding for basic neuroscience and a reason to fund further research, not evidence that any patient’s day-to-day symptoms would change.
Six Trials, One Question: Does CBDV Actually Work?
Eight perspectives on what all six peer-reviewed CBDV clinical trials show, and what marketing claims built on them tend to leave out.
If You Are Considering CBDV, Know What the Evidence Actually Shows
If you have seen CBDV marketed as a next-generation cannabinoid for seizures, autism, or pain, it is fair to ask what the human evidence actually says. Right now, the honest answer is that the two trials designed to test whether CBDV relieves a real symptom, in epilepsy and in HIV-related nerve pain, both came back negative, despite reasonably careful, well-controlled designs.
That does not mean CBDV is harmful; all six trials found it generally well tolerated with mostly mild side effects. It means the case for choosing CBDV over better-studied options currently rests on a five-patient pilot and brain-imaging studies rather than a proven clinical benefit, and that distinction is worth raising directly with your physician before you invest time or money in it.
Two Negative Trials Should Temper Enthusiasm, Not End the Conversation
As a clinician fielding questions about CBDV, the two adequately powered efficacy trials matter most: an 800 mg-dosed, 162-patient epilepsy trial and a 400 mg-dosed, 32-patient HIV neuropathic pain trial, both failed to separate from placebo on their primary endpoint. That should meaningfully temper how confidently anyone recommends CBDV over cannabinoids with a stronger evidence base for a given indication.
It does not mean the research question is closed. The Rett syndrome and neuroimaging findings are legitimate reasons to support further, better-controlled study, particularly in neurodevelopmental conditions where treatment options remain limited. But recommending CBDV today should be framed to patients as investigational, not established, therapy.
The Placebo Response Problem Deserves More Attention Than It Gets
The focal-epilepsy trial’s own authors flag something easy to miss: 36% of CBDV patients counted as seizure responders versus 33% on placebo, a narrower gap than typical epilepsy-trial placebo responses of roughly 9% to 17% reported in prior meta-analyses. A skeptical reader should ask whether that unusually high placebo response reflects trial-specific factors or expectation effects, not treat it as proof CBDV has some hidden, undetected benefit the statistics failed to capture.
The same caution cuts the opposite direction for the Rett syndrome pilot: without any placebo arm at all, there is simply no way to know how much of the reported 79% seizure reduction reflects CBDV itself versus everything else that changes when five closely monitored children enter a clinical trial.
What Full Text Confirms, and Where the Record Still Relies on Abstracts
Full text was available and reviewed for the two most consequential trials here, the 162-patient epilepsy study and the 5-patient Rett syndrome pilot, both retrieved via PubMed Central, which is why their limitations sections can be quoted directly in this review. The HIV pain trial, both neuroimaging studies, and the 2025 anti-doping trial were not available as open full text at the time of this review.
Those four are summarized here from their detailed, quantitative published abstracts rather than complete methods and results sections. That distinction matters for a critical reader: abstract-only summaries can compress nuance a full discussion section would surface, so treat those four specifically as reliable but not exhaustive, and consult the original papers before making any clinical decision.
CBDV's Story Echoes Other Minor Cannabinoids That Looked Promising Early
CBDV’s arc, encouraging preclinical and animal-model data, a small positive pilot, then a negative Phase 2 efficacy trial, mirrors what has happened with other minor cannabinoids explored for epilepsy and neurodevelopmental conditions. GW Pharmaceuticals halted its lead CBDV epilepsy program after the focal-seizure trial missed its primary endpoint in 2018, a genuine setback for a compound that had generated real scientific momentum through the 2010s.
That history is a useful reminder that mechanistic plausibility and animal data, however compelling on their own, do not reliably predict how a cannabinoid will perform once it reaches an adequately powered human efficacy trial.
The Anti-Doping Finding May Be the Most Actionable Result of All Six
For most people, the most immediately practical finding across these six trials is not about efficacy at all: the 2025 study found CBDV, along with CBG, in urine after 10 weeks of a broad-spectrum CBD supplement, with concentrations rising further after exercise. Anyone competing in a WADA-regulated sport, serving in the military, or subject to workplace cannabinoid testing should treat broad-spectrum labeling as a genuine risk factor.
That risk applies regardless of whether someone ever considers CBDV for a medical purpose. Choosing a CBD-isolate product with third-party testing for minor cannabinoid content is a concrete, low-effort way to reduce that specific exposure.
What Would Actually Change This Evidence Base
The clearest next step is a larger, adequately powered, placebo-controlled trial of CBDV in Rett syndrome or another MECP2-related condition, since that is where the strongest signal currently exists, even though it comes from an uncontrolled pilot. A confirmatory trial with real randomization and blinding could either validate or meaningfully narrow that finding within a reasonable follow-up window.
It would also be valuable to see a behavioral, symptom-level autism trial that follows up on the two neuroimaging studies, since neither has yet tested whether CBDV’s measurable brain effects translate into any change patients or caregivers would actually notice day to day.
Regulatory and Labeling Implications Worth Watching
The 2025 anti-doping trial adds concrete data to an ongoing regulatory conversation about how broad-spectrum and full-spectrum CBD products are labeled and tested, since consumers and regulated athletes currently have limited reliable ways to know which minor cannabinoids, and at what concentration, a given product actually contains. That gap has real consequences when a supplement can produce a WADA-prohibited result without THC ever being involved.
On the therapeutics side, CBDV’s negative Phase 2 epilepsy result is also a relevant data point for regulators and payers weighing how much preclinical and pilot-level evidence should be required before a minor cannabinoid is marketed with implied clinical claims.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What is CBDV, and how is it different from CBD?
Cannabidivarin (CBDV) is a non-intoxicating phytocannabinoid structurally related to CBD, found in trace amounts in most cannabis and hemp varieties. It shares some pharmacological similarities with CBD but is a distinct molecule that has been studied separately in a small number of human clinical trials.
How many clinical trials of CBDV actually exist?
A PubMed search restricted to the Clinical Trial publication type returns exactly six peer-reviewed CBDV trials, published between 2019 and 2025, spanning epilepsy, HIV-associated pain, autism-related brain imaging, and an anti-doping detection study.
Has any trial shown CBDV effectively treats epilepsy?
No. The largest and most rigorous CBDV epilepsy trial, a 162-patient Phase 2 study in adults with focal seizures, found no statistically significant difference between CBDV and placebo after 8 weeks of treatment (Brodie et al., 2021).
What about the Rett syndrome study that reported a 79% seizure reduction?
That Phase 1 trial in five girls with Rett syndrome and drug-resistant epilepsy did report a large median seizure reduction, but it had no placebo control and was not blinded or randomized, and its own authors state this makes it impossible to determine statistical significance (Hurley et al., 2022).
Does CBDV help with autism spectrum disorder?
Two single-dose neuroimaging studies found CBDV altered brain glutamate signaling and striatal functional connectivity in adults with autism, but neither trial measured behavioral symptoms, quality of life, or any clinical outcome, so they do not show CBDV improves autism symptoms.
Was CBDV tested for pain?
Yes. A randomized, double-blind, placebo-controlled crossover trial tested CBDV (400 mg/day) for HIV-associated neuropathic pain in 32 adults and found no significant pain reduction compared with placebo; the study authors concluded they would not currently consider CBDV a clinically meaningful pain treatment (Eibach et al., 2020).
Is CBDV safe?
Across all six trials, CBDV was generally well tolerated, with the most common related side effects being diarrhea, nausea, somnolence, hypersomnolence, and drooling, depending on the study population. None of the trials identified serious CBDV-related safety concerns.
Why did a 2025 study test CBDV for anti-doping, not effectiveness?
That trial examined whether daily use of a broad-spectrum CBD supplement, which is not marketed as a CBDV product, produces detectable, WADA-prohibited cannabinoids in urine. It found CBDV and CBG in a majority of samples, a safety and regulatory finding relevant to athletes and drug-tested individuals, separate from any question of CBDV's effectiveness.
Is GW Pharmaceuticals still developing CBDV as a drug?
GW Pharmaceuticals, now part of Jazz Pharmaceuticals, discontinued its lead CBDV epilepsy program after its Phase 2a focal-seizure trial missed its primary endpoint in 2018, with the peer-reviewed results published in 2021.
What would it take to know whether CBDV actually works for anything?
A larger, adequately powered, placebo-controlled trial with real blinding and randomization, ideally in the population showing the strongest early signal, such as Rett syndrome or another MECP2-related condition, or a symptom-level autism trial following up on the existing neuroimaging findings.
